Mitsubishi UFJ Trust & Banking Corp trimmed its holdings in Mednax, Inc (NYSE:MD) by 0.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 204,008 shares of the company’s stock after selling 1,396 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned about 0.22% of Mednax worth $8,797,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in MD. Great West Life Assurance Co. Can increased its holdings in shares of Mednax by 0.7% in the second quarter. Great West Life Assurance Co. Can now owns 77,858 shares of the company’s stock worth $4,698,000 after purchasing an additional 510 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of Mednax by 20.0% in the second quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock worth $181,000 after purchasing an additional 500 shares during the last quarter. Sei Investments Co. increased its holdings in shares of Mednax by 3.1% in the second quarter. Sei Investments Co. now owns 103,108 shares of the company’s stock worth $6,224,000 after purchasing an additional 3,139 shares during the last quarter. TD Asset Management Inc. increased its holdings in shares of Mednax by 1.2% in the second quarter. TD Asset Management Inc. now owns 212,947 shares of the company’s stock worth $12,856,000 after purchasing an additional 2,537 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in shares of Mednax by 5.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 295,514 shares of the company’s stock worth $17,841,000 after purchasing an additional 15,715 shares during the last quarter. Institutional investors and hedge funds own 98.48% of the company’s stock.

Several brokerages have weighed in on MD. Jefferies Group reissued a “hold” rating and set a $46.00 price objective on shares of Mednax in a research note on Tuesday, October 3rd. Robert W. Baird reissued a “hold” rating and set a $47.00 price objective on shares of Mednax in a research note on Sunday, September 3rd. KeyCorp set a $51.00 price objective on Mednax and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Citigroup reduced their price objective on Mednax from $52.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. Finally, Zacks Investment Research raised Mednax from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company’s stock. Mednax has a consensus rating of “Hold” and a consensus price target of $53.22.

In other news, Director Cesar L. Alvarez sold 10,668 shares of the company’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the transaction, the director now owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 2.40% of the company’s stock.

Shares of Mednax, Inc (NYSE MD) traded down $0.21 during midday trading on Tuesday, reaching $51.43. The company’s stock had a trading volume of 806,200 shares, compared to its average volume of 1,094,510. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.62. Mednax, Inc has a 52 week low of $40.56 and a 52 week high of $72.13. The company has a market capitalization of $4,836.36, a PE ratio of 15.79, a P/E/G ratio of 1.66 and a beta of 0.40.

Mednax (NYSE:MD) last released its earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, meeting analysts’ consensus estimates of $0.87. The firm had revenue of $868.95 million for the quarter, compared to analysts’ expectations of $864.78 million. Mednax had a return on equity of 10.80% and a net margin of 7.76%. The company’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.09 earnings per share. equities analysts predict that Mednax, Inc will post 3.1 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Mednax, Inc (MD) Shares Sold by Mitsubishi UFJ Trust & Banking Corp” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/12/mednax-inc-md-shares-sold-by-mitsubishi-ufj-trust-banking-corp.html.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.